J&J files FDA app for fast-moving cancer candidate ibrutinib

The closely watched cancer treatment ibrutinib, winner of three "breakthrough" designations from the FDA, is now ready for the agency's review. Johnson & Johnson's ($JNJ) Janssen unit delivered the new-drug application, setting the stage for an early approval. Report